

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-18 (Canceled).

19. (New) A method of treating a diet-induced fatty liver disease, the method comprising administering, to a subject in need of such treatment, an  $\alpha_1$ -adrenoreceptor antagonist, a  $\beta_2$ -adrenoreceptor agonist, or a combination thereof.

20. (New) A method according to claim 19 wherein the  $\alpha_1$ -adrenoreceptor antagonist is an  $\alpha_{1B}$ -adrenoreceptor antagonist.

21. (New) A method according to claim 19 wherein the  $\alpha_1$ -adrenoreceptor antagonist is prazosin.

22. (New) A method according to claim 19 wherein the  $\beta_2$ -adrenoreceptor agonist is isoprenaline.

23. (New) A method according to claim 19 wherein the diet-induced fatty liver disease is a non-alcoholic fatty liver disease.

24. (New) A method according to claim 20 wherein the diet-induced fatty liver disease is a non-alcoholic fatty liver disease.

25. (New) A method according to claim 21 wherein the diet-induced fatty liver disease is a non-alcoholic fatty liver disease.

26. (New) A method according to claim 22 wherein the diet-induced fatty liver disease is a non-alcoholic fatty liver disease.